Navigation Links
Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
Date:12/19/2007

Torrance-based firm will introduce NutreStore(TM) in spring 2008

TORRANCE, Calif., Dec. 19 /PRNewswire/ -- Emmaus Medical, Inc., a Torrance, California based pharmaceutical company, announced today that it has entered into an exclusive sublicense agreement with Cato BioVentures of Research Triangle Park, North Carolina for the patent protected drug NutreStore(TM) brand L-Glutamine. Under this agreement, Emmaus will commercialize NutreStore(TM), which is approved by the FDA for use in combination with human growth hormone as a treatment for short bowel syndrome (SBS). Emmaus will be introducing NutreStore(TM) in the spring of 2008 and projects that its sales will greatly contribute to its short and long term financial performance of the company.

SBS is a serious and life threatening condition afflicting around 20,000 Americans who have lost large portions of their small intestine. This leads to a malnourished condition requiring total parenteral nutrition (TPN) through intravenous feeding.

NutreStore(TM) in conjunction with human growth hormone and an appropriate diet is the first new treatment since the development of TPN for patients with short bowel syndrome. Clinical studies of this combination therapy administered to SBS patients dependent upon TPN for nutritional support showed a significant reduction in the required weekly volume, caloric content and frequency of TPN administration compared to patients treated with human growth hormone alone. "This combination therapy offers patients a unique opportunity to improve intestinal absorption of food, which leads to a much better quality of life for SBS patients," said Douglas Wilmore, M.D., a board member of Emmaus. Dr. Wilmore is an Emeritus Frank Sawyer Professor of Surgery at Harvard Medical School, the inventor of this SBS treatment, and Editor-in-Chief of the Medscape General Surgery section of Medscape Today, at http://www.WebMD.com.

Currently, patients who require L-Glutamine must purchase non-pharmaceutical grade L-Glutamine on their own without insurance coverage. With a prescription, NutreStore(TM) will be covered by insurance, thus lifting a large financial burden from patients who wish to optimize their SBS treatment with an FDA approved pharmaceutical product.

"Cato BioVentures is excited to partner with Emmaus Medical for the marketing of NutreStore(TM) and looks forward to a long and successful relationship with the company," said Joel Eisner, Ph.D., Associate Principal of Cato BioVentures.

About Emmaus Medical, Inc.

Emmaus Medical, Inc., led by Yutaka Niihara, M.D., M.P.H., CEO, and Daniel R. Kimbell, Esq., COO, is a private company founded to develop new treatments for sickle cell disease and other orphan diseases such as SBS. Emmaus works closely with the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) and is currently conducting multi-center, double blind, placebo controlled, clinical trials to determine the safety and efficacy of L-Glutamine for sickle cell disease. Emmaus Medical is the recipient of an FDA orphan drug designation and fast track designation for the sickle cell project. For more information, please visit our website http://www.emmausmedical.com.

About Cato BioVentures

Cato BioVentures is the venture capital affiliate of Cato Research Ltd. For nearly 20 years, Cato BioVentures has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic CRO service agreements with Cato Research, Cato BioVentures invests its in-kind CRO Service Capital in innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has offices in Boston's Bay Colony, Research Triangle Park and Silicon Valley. For more information, please visit our website http://www.catobioventures.com.

Contact:

Henry Macan, M.D., Senior Manager

Emmaus Medical, Inc.

3870 Del Amo Boulevard, Unit 507

Torrance, CA 90503-7701

Tel. 310.214.0065

Email: hmacan@emmausmedical.com

Joel Eisner, Ph.D., Associate Principal

Cato BioVentures

4364 South Alston Avenue

Durham, NC 27713

Tel. 919-361-2286

Email: jeisner@cato.com


'/>"/>
SOURCE Emmaus Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
11. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: